# US 2002/0054917 A1 · Compositions comprising beta glucan and lactoferrin, and methods for their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0054917 A1
- Document ID: US20020054917A1
- Status: Published application
- Kind: A1
- Application number: 10/021,970
- Filed: 2001-12-13
- Published: 2002-05-09
- Earliest claimed: 1998-08-14
- Inventors: Marcus B. Gohlke
- Web page: https://patentgrep.com/patent/US20020054917A1

## CPC

- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A23C 9/206: {Colostrum; Human milk}
- A23L 33/19: Dairy proteins
- A61K 38/40: Transferrins, e.g. lactoferrins, ovotransferrins
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A23V 2250/54248: Lactoferrin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23C: DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF (preservation thereof A23B11/00)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

Dietary supplement compositions containing beta glucan and lactoferrin are disclosed. The compositions can be formulated as a liquid, tablet, lozenge, gum, or other acceptable forms. The compositions can further contain flavorings, carriers, or diluents. The compositions can be used in a nutritional program to enhance the activity of macrophages and neutrophils, leading to an improved ability to fight infection from bacterial, fungal, and viral challenges.

## Claims

### Claim 1

A composition comprising beta glucan and lactoferrin.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the composition is a solid.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the composition is in the form of a capsule, lozenge, chewable lozenge, tablet, chewable tablet, or chewable gum.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the composition is a liquid.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the beta glucan is mushroom beta glucan, yeast beta glucan, or oat beta glucan.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the beta glucan is yeast cell wall beta glucan.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the concentration of beta glucan is about 1 weight percent to about 10 weight percent.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the lactoferrin is mammalian lactoferrin.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the lactoferrin is bovine milk lactoferrin.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the concentration of lactoferrin is about 0.25 weight percent to about 2.5 weight percent.

### Claim 11 (depends on 1)

The composition of claim 1, wherein:
the concentration of beta glucan is about 1 weight percent to about 10 weight percent; and
the concentration of lactoferrin is about 0.25 weight percent to about 2.5 weight percent.

### Claim 12 (depends on 1)

The composition of claim 1, further comprising at least one nutritionally acceptable carrier.

### Claim 13 (depends on 1)

The composition of claim 1, further comprising at least one nutritionally acceptable diluent.

### Claim 14 (depends on 1)

The composition of claim 1, further comprising at least one nutritionally acceptable flavoring.

### Claim 15 (depends on 1)

The composition of claim 1, wherein the composition is prepared in an oral dose specific format that promotes absorption of the composition's components within the mucosal layer in the oral cavity.

### Claim 16

A composition comprising:
about 1 weight percent beta glucan to about 3 weight percent beta glucan;
about 0.5 weight percent lactoferrin to about 1.5 weight percent lactoferrin; and
about 5 weight percent nutritionally acceptable flavoring to about 7 weight percent nutritionally acceptable flavoring.

### Claim 17

A composition comprising:
about 2 weight percent beta glucan;
about 1 weight percent lactoferrin; and
about 5.7 weight percent nutritionally acceptable flavoring.

### Claim 18

A composition consisting essentially of:
about 2 weight percent beta glucan;
about 1 weight percent lactoferrin;
about 5.7 weight percent lemon flavoring;
about 50 weight percent mannitol;
about 40.8 weight percent sorbitol; and
about 0.5 weight percent silicon dioxide.

### Claim 19

A method of treating an individual afflicted with cancer, the method comprising administering to the individual a composition comprising beta glucan and lactoferrin.

### Claim 20

A method of treating an individual infected with bacteria, the method comprising administering to the individual a composition comprising beta glucan and lactoferrin.

### Claim 21

A method of treating an individual infected with a fungus, the method comprising administering to the individual a composition comprising beta glucan and lactoferrin.

### Claim 22

A method of treating an individual infected with a virus, the method comprising administering to the individual a composition comprising beta glucan and lactoferrin.

### Claim 23

A method of treating an individual afflicted with septicemia, the method comprising administering to the individual a composition comprising beta glucan and lactoferrin.

### Claim 24

A method of preventing or delaying the onset of septicemia in an individual, the method comprising administering to the individual a composition comprising beta glucan and lactoferrin, whereby the onset time of septicemia is longer than the onset time of a similar individual to whom the composition is not administered.
